This trial is enrolling 30 participants with chronic spinal cord injury to test the safety and tolerability of psilocybin, a hallucinogenic drug that activates specific pathways in the nervous system that regulate a number of body functions, including mood, and may influence symptoms of major depression. If included, participants will take psilocybin by mouth at one of three dose levels (5 mg, 10 mg, or 25 mg) across seven site visits. Participants will not know the dose they receive. Each will also attend additional in-person and remote follow-up visits, and maintain symptom and unexpected or harmful event logs over 1 year. Final testing of safety and tolerability will be performed after 13 months.
Type
Details
- Participants will take psilocybin at one of three dose levels (5 mg, 10 mg, or 25 mg) across seven core visits, attend additional in-person and remote follow-up visits, and maintain symptom and adverse-event logs over 1 year. - Psilocybin is a drug that activates serotonin pathways in the nervous system and may influence symptoms of major depression. - Final testing of safety and tolerability will be performed after 13 months.
Main benefits
Mental health and psychosocial factors
Additional benefits
General health
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn moreWings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more